Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report

Endocr Metab Immune Disord Drug Targets. 2024;24(4):495-498. doi: 10.2174/0118715303241179230927105454.

Abstract

Background: Hereby, we describe the first case of latent mastocytosis triggered by mRNA-based vaccine to prevent COVID-19 infection.

Case presentation: In a 42-year-old Arabian man affected by slight, undiagnosed mastocytosis, the second dose of the COVID-19 vaccine made more blatant his latent disease. The postvaccination diagnostic iter is illustrated and the potential reasons causing the onset of the cutaneous mastocytosis are discussed.

Conclusion: Clinicians should keep a longer follow-up of their patients after the COVID-19 vaccination, not related to few hours, for the risk of immediate-type adverse events only.

Keywords: COVID-19 vaccine; Pfizer-BioNTech.; mRNA-based vaccine; mast cell activation; mastocytosis; serum mast cell tryptase.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • BNT162 Vaccine / adverse effects
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / complications
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Humans
  • Male
  • Mastocytosis / diagnosis
  • Mastocytosis / immunology
  • Mastocytosis, Cutaneous / diagnosis
  • Mastocytosis, Cutaneous / immunology
  • SARS-CoV-2 / immunology
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine